These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Halogenated monopyridinium oximes are less effective in reactivation of phosphylated cholinesterases than bisquaternary oximes. Kohoutova Z, Prchalova E, Andrys R, Knittelova K, Formanova M, Hofmanova T, Psotka M, Musilek K, Derat E, Malinak D. Bioorg Chem; 2024 Dec; 153():107904. PubMed ID: 39467508 [Abstract] [Full Text] [Related]
5. Halogen substituents enhance oxime nucleophilicity for reactivation of cholinesterases inhibited by nerve agents. Zorbaz T, Malinak D, Hofmanova T, Maraković N, Žunec S, Hrvat NM, Andrys R, Psotka M, Zandona A, Svobodova J, Prchal L, Fingler S, Katalinić M, Kovarik Z, Musilek K. Eur J Med Chem; 2022 Aug 05; 238():114377. PubMed ID: 35526478 [Abstract] [Full Text] [Related]
6. Testing of novel brain-penetrating oxime reactivators of acetylcholinesterase inhibited by nerve agent surrogates. Chambers JE, Chambers HW, Meek EC, Pringle RB. Chem Biol Interact; 2013 Mar 25; 203(1):135-8. PubMed ID: 23123249 [Abstract] [Full Text] [Related]
7. Kirtsoglou E, Simpson B, Salisbury L, Baraitser L. ; 2020 Mar 25. PubMed ID: 36137063 [Abstract] [Full Text] [Related]
8. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu ZZN, Wittmann M. Health Technol Assess; 2024 Jan 25; 28(4):1-113. PubMed ID: 38343072 [Abstract] [Full Text] [Related]
9. Reactivation of organophosphate-inhibited serum butyrylcholinesterase by novel substituted phenoxyalkyl pyridinium oximes and traditional oximes. Nichols RH, Chambers JE. Toxicology; 2021 Mar 30; 452():152719. PubMed ID: 33592259 [Abstract] [Full Text] [Related]
10. Efficient Access to New Thienobenzo-1,2,3-Triazolium Salts as Preferred Dual Cholinesterase Inhibitors. Mlakić M, Sviben M, Ratković A, Raspudić A, Barić D, Šagud I, Lasić Z, Odak I, Škorić I. Biomolecules; 2024 Oct 31; 14(11):. PubMed ID: 39595567 [Abstract] [Full Text] [Related]
13. Point-of-care tests for urinary tract infections to reduce antimicrobial resistance: a systematic review and conceptual economic model. Tomlinson E, Ward M, Cooper C, James R, Stokes C, Begum S, Watson J, Hay AD, Jones HE, Thom H, Whiting P. Health Technol Assess; 2024 Nov 31; 28(77):1-109. PubMed ID: 39644102 [Abstract] [Full Text] [Related]
14. Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis. Shabaninejad H, Kenny RP, Robinson T, Stoniute A, O'Keefe H, Still M, Thornton C, Pearson F, Beyer F, Meader N. Health Technol Assess; 2024 Oct 31; 28(75):1-75. PubMed ID: 39487741 [Abstract] [Full Text] [Related]
15. Trends in Surgical and Nonsurgical Aesthetic Procedures: A 14-Year Analysis of the International Society of Aesthetic Plastic Surgery-ISAPS. Triana L, Palacios Huatuco RM, Campilgio G, Liscano E. Aesthetic Plast Surg; 2024 Oct 31; 48(20):4217-4227. PubMed ID: 39103642 [Abstract] [Full Text] [Related]
16. Effects of the nerve agent VX on hiPSC-derived motor neurons. Schaefers C, Schmeißer W, John H, Worek F, Rein T, Rothmiller S, Schmidt A. Arch Toxicol; 2024 Jun 31; 98(6):1859-1875. PubMed ID: 38555327 [Abstract] [Full Text] [Related]
17. A structure-activity analysis of the variation in oxime efficacy against nerve agents. Maxwell DM, Koplovitz I, Worek F, Sweeney RE. Toxicol Appl Pharmacol; 2008 Sep 01; 231(2):157-64. PubMed ID: 18508103 [Abstract] [Full Text] [Related]